Immutep Reports Positive Phase II Results for Eftilagimod Alfa in Soft Tissue Sarcoma

Immutep Ltd. has announced positive results from the Phase II EFTISARC-NEO clinical trial, which evaluates the novel immunotherapy agent eftilagimod alfa (efti) as a neoadjuvant treatment for soft tissue sarcoma. Data from the study were presented in an oral session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting. The trial demonstrated significant immune system activation and a 51.5% rate of tumour hyalinization and fibrosis across multiple sarcoma subtypes, including rare and aggressive forms. The study also reported statistically significant increases in several immune biomarkers and cytokines, supporting the potential of efti in earlier-stage disease settings. The EFTISARC-NEO project received the Golden Scalpel Award in Poland, recognizing its innovation and impact in oncology research. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-280784), on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here